Allogene Therapeutics Inc. (ALLO) Is A Stock You Should Watch

As of Friday close, Allogene Therapeutics Inc.’s (NASDAQ:ALLO) stock was up $0.74, moving up 5.03 percent to $15.46. The average number of shares traded per day over the past five days has been 1,657,720 shares. 4 times new highs have been achieved over the past 5 days, with a $2.48 gain in that time frame. In the last twenty days, the average volume was 1,533,215, while in the previous 50 days, it was 2,042,408.

Since last month, ALLO stock rose 32.02%. Shares of the company fell to $10.46 on 07/12/22, the lowest level in the past month. A 52-week high of $27.86 was reached on 08/05/22 after having rallying from a 52-week low of $6.43. Since the beginning of this year, ALLO’s stock price has risen by 3.62% or $0.54, and marked a new high 2 times. However, the stock has declined by -44.51% since its 52-week high.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .


Allogene Therapeutics Inc. (ALLO) last reported insider trading activity 4 days ago on Aug 02. Amado Rafael, the EVP of R&D and CMO of the company, disposed of 2,000 shares for $11.97 on Aug 02. It resulted in a $23,940 divestment by the insider. Amado Rafael sold 2,000 shares at an average price of $11.44 on Jul 05. The insider now owns 542,257 shares following the transaction. On Jun 22, Director WITTE OWEN N. sold 10,000 shares at $11.76 apiece. The transaction was valued at $117,600.

Valuation Metrics

The stock’s beta is 0.55. Besides these, the trailing price-to-sales (P/S) ratio of 11972.22, the price-to-book (PB) ratio of 2.56.

Financial Health

In the three months ended March 30, Allogene Therapeutics Inc.’s quick ratio stood at 12.70, while its current ratio was 12.70, showing that the company is able to pay off its debt. Based on annual data, ALLO earned $294.28 million in gross profit and brought in $38.49 million in revenue.

A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -27.90%. Return on equity (ROE) for the past 12 months was -32.30%.

According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. ALLO’s revenue fell -63816.67% during the quarter, while net income inched up to $60000.0. While analysts expected Allogene Therapeutics Inc. to report -$0.58 quarterly earnings, the actual figure was -$0.56 per share, beating the consensus estimate by 3.40%. During the quarter, the company generated -$74.97 million in EBITDA. The liabilities of Allogene Therapeutics Inc. were 109.4 million at the end of its most recent quarter ended March 30, and its total debt was $72.62 million. The value of shareholders’ equity is $143.6 million.

Technical Picture

This quick technical analysis looks at Allogene Therapeutics Inc.’s (ALLO) price momentum. With a historical volatility rate of 81.39%, the RSI 9-day stood at 70.59% on 05 August.

With respect to its five-day moving average, the current Allogene Therapeutics Inc. price is up by +19.11% percent or $2.48. At present, ALLO shares trade +28.51% above its 20-day simple moving average and +102.09% percent above its 100-day simple moving average. However, the stock is currently trading approximately +110.63% above its SMA50 and -1.78% below its SMA200.

Stochastic coefficient K was 86.11% and Stochastic coefficient D was 64.25%, while ATR was 1.07. Given the Stochastic reading of 98.90% for the 14-day period, the RSI (14) reading has been calculated as 67.46%. As of today, the MACD Oscillator reading stands at 1.02, while the 14-day reading stands at 0.96.

Analyst Ratings

Goldman upgraded its rating on Allogene Therapeutics Inc. (NASDAQ: ALLO) to a Buy in a note to investors on July 15, 2022. The analysts firm previously had a Neutral rating on the stock.Allogene Therapeutics Inc. (ALLO) has been rated Buy by analysts. According to 0 brokerage firms, ALLO is a sell, and 4 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 1 analyst rate Allogene Therapeutics Inc. stock as buy, with 14 recommending it as overweight.

With a median target price of $24.00, the current consensus forecast for the stock is $11.00 – $55.00. Based on these forecasts, analysts predict Allogene Therapeutics Inc. (ALLO) will achieve an average price target of $27.06.


Please enter your comment!
Please enter your name here

Hot Topics

Related Articles